Registration: The Science and Practice of Treating Pregnant Women with Opioid Use Disorder - In Person Training
Opioid use disorder (OUD) in the US continues to rise, including among women of childbearing age. Pregnant women with opioid use disorder face many barriers to care, including stigma, limited access to treatment, and fear of legal consequences. The speaker will cover the science and best practices in treating pregnant women with OUD and their infants, as well as a panel focused on case review and discussion.
1. Evaluate three research-based practices to treat pregnant women with opioid use disorder
2. Recognize barriers that may impede care for pregnant women with OUD
3. Summarize three signs of neonatal abstinence syndrome in opioid-exposed infants
4. Develop strategies to effectively diagnose and treat your pregnant or postpartum patient with OUD.
Additional Topics related to MAT Providers: Best practices in admitting and treating pregnant and postpartum women with OUD. Talking with patients about the various medications to treat OUD. Best practices for treating OUD with the added complications of a benzodiazepine or alcohol use disorder during pregnancy Best practices for inducting medication for OUD in pregnant women. Best practices in referring pregnant patients to a higher level of care. Best practices for changing OUD medications and changing dosage during pregnancy. Addressing and reducing liability concerns with this population.
Additional Topics related to OB Providers: Partnering with substance use providers, coordination of care with SUD provider. Determining the most appropriate level of care to refer pregnant substance using patients to. Talking with patients about the various medications to treat OUD. .Best practices for treating OUD with the added complications of a benzodiazepine or alcohol use disorder during pregnancy. Best practices for inducting medication for OUD. Best practices for changing OUD medications and changing dosage during pregnancy. Addressing and reducing liability concerns with this population.
Continuing Education Units:
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint providership of the University of Nevada, Reno School of Medicine and the Center for the Application of Substance Abuse Technologies. The University of Nevada, Reno School of Medicine is accredited by the ACCME to provide continuing medical education to physicians.
The University of Nevada, Reno School of Medicine designates this live activity for a maximum of 3.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The University of Nevada, Reno School of Medicine approves this program for 3.00 hours of nursing continuing education credit.
The University of Nevada, Reno School of Medicine is a provider of continuing education credit through the Nevada State Board of Pharmacy. This program is approved for 3.00 hours of continuing education credit for pharmacists.
Funding for this initiative was made possible (in part) by grant no. 6H79TI080816 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.